Study characteristics |
|
Patient sampling |
Cross-sectional design with convenience-based enrolment of participants, retrospective data collection |
Patient characteristics and setting |
Country of origin: Netherlands
World Bank classification of country: high
Type of lab: reference
Type of patients: confirmed MDR-TB cases, confirmed MDR-TBs with some known second-line resistance
|
Index tests |
Manufacturer involvement: no
Type of testing: indirect
|
Target condition and reference standard(s) |
Culture (solid; 7H10)
FQ drugs: moxifloxacin (1 µg/mL)
SLIDs: amikacin (5 µg/mL) and capreomycin (10 µg/mL). WHO critical concentrations not used for 7H10 solid culture
Discrepant analysis: no
|
Flow and timing |
Uninterpretable results reported: yes |
Comparative |
|
Notes |
Relevant clinical information? unclear |
Methodological quality |
|
Item |
Authors' judgement |
Risk of bias |
Applicability concerns |
DOMAIN 1: Patient Selection |
|
Was a consecutive or random sample of patients enrolled? |
No |
|
|
Was a case-control design avoided? |
No |
|
|
Did the study avoid inappropriate exclusions? |
Yes |
|
|
|
|
|
High |
DOMAIN 2: Index Test All tests |
|
Were the index test results interpreted without knowledge of the results of the reference standard? |
Yes |
|
|
If a threshold was used, was it pre-specified? |
Yes |
|
|
|
|
|
Low |
DOMAIN 3: Reference Standard |
|
Is the reference standards likely to correctly classify the target condition? |
No |
|
|
Were the reference standard results interpreted without knowledge of the results of the index tests? |
Yes |
|
|
|
|
|
Low |
DOMAIN 4: Flow and Timing |
|
Was there an appropriate interval between index test and reference standard? |
Yes |
|
|
Did all patients receive the same reference standard? |
Yes |
|
|
Were all patients included in the analysis? |
Yes |
|
|
|
|
|
|